Amgen's PCSK9 Patent Win: A Long-Term Value Shift?

Amgen Inc. may have won a battle in its lawsuit involving two patents on its proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor Repatha (evolocumab) against Sanofi SA and Regeneron Pharmaceuticals Inc., which market a competing drug, Praluent (alirocumab), but the California biotech giant is far from winning the war – that is, making the prophesied blockbuster profits on its medicine.